221 related articles for article (PubMed ID: 35870899)
1. A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
Li A; Ambruso SL; Oto OA; Barry M; Edelstein CL
BMC Nephrol; 2022 Jul; 23(1):264. PubMed ID: 35870899
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
3. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
Maynard SE; Min JY; Merchan J; Lim KH; Li J; Mondal S; Libermann TA; Morgan JP; Sellke FW; Stillman IE; Epstein FH; Sukhatme VP; Karumanchi SA
J Clin Invest; 2003 Mar; 111(5):649-58. PubMed ID: 12618519
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib-induced acute kidney injury via interstitial nephritis.
Markóth C; File I; Szász R; Bidiga L; Balla J; Mátyus J
Ren Fail; 2021 Dec; 43(1):335-339. PubMed ID: 33567947
[TBL] [Abstract][Full Text] [Related]
5. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
6. Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia.
Mutluay R; Aki SZ; Erten Y; Konca C; Yagci M; Barit G; Sindel S
Clin Nephrol; 2008 Dec; 70(6):527-31. PubMed ID: 19049712
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
8. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
[TBL] [Abstract][Full Text] [Related]
10. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
12. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C
Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
Brener ZZ; Brener H; Losev A
J Oncol Pharm Pract; 2020 Oct; 26(7):1735-1737. PubMed ID: 32054411
[TBL] [Abstract][Full Text] [Related]
14. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor.
Holwerda KM; Burke SD; Faas MM; Zsengeller Z; Stillman IE; Kang PM; van Goor H; McCurley A; Jaffe IZ; Karumanchi SA; Lely AT
J Am Soc Nephrol; 2014 Apr; 25(4):717-25. PubMed ID: 24335973
[TBL] [Abstract][Full Text] [Related]
16. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
Rhodes JM; LoRe VA; Mato AR; Chong EA; Barrientos JC; Gerson JN; Barta SK; Landsburg DJ; Nasta SD; Svoboda J; Loren AW; Schuster SJ
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):438-444.e1. PubMed ID: 32197990
[TBL] [Abstract][Full Text] [Related]
18. A case of Takayasu arteritis complicated with glomerulonephropathy mimicking membranoproliferative glomerulonephritis: a case report and review of the literature.
Kuroda T; Ueno M; Sato H; Murakami S; Sakatsume M; Nishi S; Nakano M; Gejyo F
Rheumatol Int; 2006 Nov; 27(1):103-7. PubMed ID: 16830159
[TBL] [Abstract][Full Text] [Related]
19. The glomerular injury of preeclampsia.
Stillman IE; Karumanchi SA
J Am Soc Nephrol; 2007 Aug; 18(8):2281-4. PubMed ID: 17634433
[TBL] [Abstract][Full Text] [Related]
20. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
